Pyoderma gangrenosum of the “sinus mammarum”

in ulcerative colitis by Angiò, Luigi Giuseppe et al.
G Chir Vol. 24 - n. 6/7 - pp. 247-254
Giugno-Luglio  2003
Pyoderma gangrenosum of the “sinus mammarum”
in ulcerative colitis
L.G. ANGIÒ, G. PIRRONE, G. RIVOLI, M.G. FRACASSI, A. ROSATO,
E. PIAZZESE, V. PACILÉ, G. SFUNCIA, F. FIUMARA
247
Introduction
As far as the alimentary canal is concerned, ulcera-
tive colitis (UC) is by definition an organ disease in
the sense that it does not go beyond the limits of the
colon-rectum area; all the same, in 14-36% of cases,
during the course of the illness, extraintestinal com-
plications can be observed in tissues and organs apart
f rom the colon-rectum, which is without doubt an
i m p o rtant prognosis factor because of its import a n t
contribution to the morbidity and mortality of the
patients (12, 22, 56, 71).
The spectrum of extracolonic diseases that can be
linked to UC include - in decreasing order of fre-
quency: osteo-articular lesions (sieronegative poliarth-
ritis, ankylosing spondylitis, sacroileitis), cutaneous
(nodosum erythema, pyoderma gangrenosum, papulo-
n e c rotic lesions and ve s i c u l o p u s t u l a r, polymorphic
e rythema, aphthous ulcerations), hepatobiliary (peri-
colangitis, hepatitis, cirrhosis, sclerosing cholangitis),
ocular (uveitis, iritis, episcleritis) and a wide range of
renal, vascular and haematological complications (1,
12, 22, 56).
The incidence of unhealthy skin disorders in
patients with UC oscillates between 1.7% and 34% (3,
5, 20, 22, 26, 30, 59); the worst of these is pyo d e r m a
g a n g renosum (PG), an inflammatory, necrotizing, ulce-
r a t i ve skin disease, first re p o rted in 1929 by Bargen (2).
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The first part of this article deals with the report of a patient suffe -
ring from pyoderma gangrenosum of the “sinus mammarum” associa -
ted with asymptomatic ulcerative colitis. This is followed by a revision
of the present epidemiological, etiological, pathogenetic and clinical
knowledges about this systemic manifestation of chronic phlogosis of the
colon. 
The Authors have analysed the treatment for this condition and
emphasized the resistance of the cutaneous ulcer encountered to conven -
tional medical therapy of the underlying colonic disease which proved
to be efficacious only on the latter; this led to integrate traditional
treatment with the use of perilesional injections of small doses of calcic
heparin as an alternative to immunosuppressive drugs or surgery.
Topical antithrombotic treatment, which can be justified by the histo -
logical findings of phenomena of the vasculitis in the edge of pyoderma
gangrenosum, demonstrated to be crucial and represents a peculiarity
in the case here reported, which is unique in the literature as far as the
Authors know, since it has not been experimented by anyone else.
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Gli Autori, prendendo spunto dall’osservazione di una paziente
con pioderma gangrenoso del “sinus mammarum” in corso di colite
ulcerosa asintomatica, fanno una revisione delle attuali conoscenze
epidemiologiche, eziopatogenetiche e cliniche su questa manifestazio -
ne sistemica della flogosi cronica del colon. 
Essi ne analizzano, inoltre, l’approccio terapeutico e sottolineano
la refrattarietà dell’ulcera cutanea alla convenzionale terapia medica
della malattia colica sottostante, efficace in effetti solo per questa, che
li conduce, in alternativa a trattamenti immunosoppressivi o
all’opzione chirurgica, ad associare l’impiego di iniezioni perilesionali
di piccole dosi di eparina calcica. Il trattamento topico antitromboti -
co, che trova il suo razionale nel riscontro istologico di fenomeni
vasculitici a carico dei margini del pioderma gangrenoso, si dimostra
risolutivo e rappresenta una peculiarità del caso clinico illustrato,
unico in letteratura a quanto è dato di sapere, non essendo stato da
altri sperimentato. 
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We consider worthy of note the case of a patient
with PG associated to UC; the UC condition was not
obvious at the onset of the cutaneous lesion which was
in fact the initial manifestation of it. This example
enriches the case-re c o rd of extraintestinal complica-
tions of UC and it is also important because of the
unusual place of the onset of PG - the “sinus mamma-
rum”. Other important aspects are the light-to-mode-
rate seriousness and the limited extension of the
underlying disease, the resistance of the PG to conven-
tional medical treatment of UC, to which the UC
responds, and the fact that we obtained results with the
additional use of perilesional injections of small doses
of calcic heparin instead of immunosuppressive drugs
or surgery. The additional, topical antithro m b o t i c
treatment, based on the histological findings of pheno-
mena of the vasculitis in the edge of the cutaneous
ulcer, represents a peculiarity in our case, which is uni-
que in the literature as far as we know, since it has not
been experimented by anyone else.
Case repor t
B.E., a 36-year-old married housewife with children, was
admitted to our ward with the diagnosis of “ulcerative lesion of the
sternum area”.
The family, physiological and distant pathological background
did not show any important information nor did they show up
pathologies worthy of note.
The patient dated the onset of the disease to about 15 days
before, going into hospital when she noted the appearance between
her breasts of a nodule the shape and size of a large grain of rice,
covered with reddened edematous skin, which was hard and pain-
ful both spontaneously and to the touch. At first she tought it was
the beginning of a boil and was further convinced of this idea when
the initial lesion subsequently changed into a protruding pustule
and the secondary spontaneous draining of this produced purulent
m a t e r i a l .
Over the next few days the patient noticed that a scab did not
form, which is usually part of the healing process of a boil, but that
there was the residue of an ulcer which was still particularly painful
and which spread rapidly until it reached its present size, despite
the unspecified topical treatment prescribed by the family doctor.
After an examination of the patient, who was generally in rea-
sonable health, no pathological elements emerged which are worth
mentioning, apart from a clear state of anxiety and depression,
which a careful psychological examination of the patient revealed
that this seems to be have existed before the onset of the cutaneous
lesion and to have been motivated by a degeneration of marital rela-
t i o n s . We focussed our attention on the ulceration in the “sinus
mammarum” which had extended asymmetrically towards the left
breast. The oval-shaped lesion, with a larger transversal diameter
measured about 6x5 cm; it had thin, frayed cribrate edges with ope-
nings from which creamy puruloid material oozed, sometimes coa-
gulated and stuck to the bottom, not bleeding, soft and painful to
the touch, undermining and formed of atrophic skin, prone to
necrotic phenomena, cyanotic purple in colour, surrounded by
haloes of erithematous skin; the base, formed by the sub-cutaneous,
was reddy-orange coloured, mamelonated and moist because of
siero-torbid secretions (Fig. 1A).
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Fig. 1- The ulcerative lesion - A. On the patient’s arrival in the ward; B. On
the sixth day of hospitalization; C. On the day after topical antithrombotic
treatment. There are some small petechias in the sites of the perilesional
injections of calcic heparin; D. On the 36th day from the beginning of topi-
cal antithrombotic treatment (the perilesional injections of calcic heparin
were carried out on alternate days only during the first 24 days). Signs of
positive change are evident: reduced dimensions and trophic edges; E.
On the 48th day from the beginning of topical antithrombotic treatment (the
perilesional injections of calcic heparin were carried out on/in alternate
days only during the first 24 days). At the moment there is a serpiginous
scar, with skin atrophia and dyschromia; there is still some very superfi-
cial area of cruentation.
Fig. 2 - A and B - Biopsy specimen from the edge of ulcerative lesion
demonstrates a substantial inflammatory infiltrate in the papillary dermis,
mainly around the vessels; this is prevalently formed of lympho-histiocyte
elements and acidocytes.
The routine laboratoy investigations indicated hypochromic-
hyposideremic anaemia (RBC 4.060.000/mm3; haemoglobin
10.5g%; hematocrit 26%; sideraemia 32 ng/dl) and leukocytosis
with a movement towards the left o f the formula (WBC
1 3 . 4 0 0 / m m3; 82% of neutrofils); thrombocytosis was present
(PLT 565.000/mm3). Serum protein electrophoresis showed a
decrease of total proteins (4.9 g/dl) and albumin levels (42.8%) and
an increase of alpha1 - (8.7%) and alpha2-globulin (16.9%).
Serum electrolytes levels and hepatic and renal functional activity
were all within the normal range. Aspecific indices of phlogosis
appeared to have increased (ESR 45 in the first hour; CRP 20.5
mg/l; fibrinogen 608 mg/dl).
A standard radiography of the thorax was taken; this produced
a negative result because of pleuro-pulmonary and bony nidal
lesions on the thoracic cage.
We sampled exudate for bacterioscopy and culture of KB and
for isolation of bacteria and fungi.
At the same time we carried out a biopsy from the edges of the
lesion for histological study. While waiting for te results, the
patient underwent suitable treatment for the disorders found in the
laboratory tests; moreover we carried out treatment with a wide
spectrum of antibiotics and drugs against anxiety.
Each day, after lavage with a physiological hydroelectrolytic
solution, the ulcerative lesion was medicated, alternating
“IntraSite Gel” by Smith + Nephew, which is useful for its clean-
sing effect, with Actisorb Plus by Johnson&Johnson Ethicon,
which has an absorbent action on organic material, exudate and
contaminated bacteria and it also has an antimicrobial action; after
each medication the basic pain felt by the patient increased and
lasted for several hours. During the first six days of treatment the
cutaneous lesion spread very slowly in a centrifugal way towards
the right and at a speed of about 0.5 cm a day towards the left
breast and reached te size of about 9x6 cm; in particular the edges,
which the day before had looked separate from the base, the next
day looked necrotic and cribrate, secreting pus-like material.
However we did not note a further spreading deep in the subcutis;
the base, on the right side especially, looked to be cleansed and
granular in parts (Fig. 1B).
The medication was sealed daily so it could not be tampered
with; this excluded the possibility of pathomimesis.
The cultures from the ulcer were negative and the histological
examination of the biopsy showed the presence of a substantial
inflammatory infiltrate, which was located in the papillary dermis,
particularly around the vessels, and was composed mostly of eosi-
nicytes, histiocytes and lymphocytes; moreover the examination
documented vasculitis features and these findings are consistent
with the diagnosis of pyoderma gangrenosum, because of the pecu-
liarities of the scene (Figs. 2A and B).
Because of the prevalent association of this lesion with a chro-
nic inflammatory bowel disease, even in the absence of any specific
symptomatology, we carried out a coloscopy which showed up
edema, hyperaemia and loss of the normal vascular pattern of
mucosa of the rectosigmoid tract, which was friable and easily bled
when touched, an aspect which is compatible with a case of UC,
confirmed by phlogosis of the lamina itself and by the undermining
of the glandular structures revealed by the histological examination
together with wide areas of superficial erosion.
At this stage, the laboratory investigations were completed
with the study of other aspecific indications of phlogosis (alpha-1
glycoprotein serum and alpha-1 antitrypsin serum) and, on the
basis of immunomediate pathogenetic hypothesis of UC and its
extraintestinal complications, with the study of the immunologi-
cal aspect (lymphocyte typing; assay of serum gammaglobulin;
complement; circulating immunocomplexes; autoantibodies); in
this field, we draw attention to the slight decrease of the C3 frac-
tion of the complement (43 mg/dl), to the presence of circulating
immunocomplexes (28 mcgEQ/ml) and to the negative result of
all autoimmune markers. The test for occult blood in the feces
proved positive.
The patient was immediately given specific systemic treatment
with oral mesalazine (3x800 mg/day) and full dose of oral predni-
sone (2x50 mg/day, equivalent to 2 mg/kg of body gravity/day);
moreover, mesalazine (2 g) and hydrocortisone (125 mg) enemas
were also administred twice a day. The support treatment was kept
up, associating suitable gastric protection with ranitidine and
sucralphate.
For the first 10 days of this treatment, the PG carried on with
its rapid, destructive action in a centrifugal direction, continuing
to extend almost exclusively towards the left breast and in a cranio-
caudal way, until it reached the dimensions of 13.5x9.5 cm; the
base presented characteristics of evident cleansing even on the left
side and in the area near the border of “advance”, and it looked gra-
nular. Before taking the almost obligatory decision to carry out
immunosuppressive treatment, which is not without complica-
tions, a rectosigmoidoscopy was carried out which showed an
improvement of the bowel scene, in stark contrast to the worsening
of the cutaneous lesion. The results of all laboratory tests were
within the normal range. At this point, we decided to leave the spe-
cific treatment unchanged and to supplement it on alternate days
with infiltrations on the edges of the lesion, especially those of the
greatest activity of the disease, with small doses of calcic heparin
(5000 UI of calcic heparin were diluted in 10 cc of physiological
solution with which 10 perilesional injections were carried out);
the aim of this was to exploit the antithrombotic action of the cal-
cic heparin on the phenomena already documented of vasculitis
(Fig. 1C).
From the 6t h day of antithrombotic topical treatment we noti-
ced the arrest of the centrifugal extension of the cutaneous lesion,
whose edges on the 12t h day no longer looked mortified and the
ulcer base still appeared cleansed and granular; in order to prevent
the formation of a hypertrophic scar or a keloid, we proceeded to
treat the ulcer base by the adhesive medication of si licone
Mepiform by Tendra, which substituted the previous topical treat-
m e n t . From the 12th day, while the granulation tissue continued to
fill the loss of substance, we noticed the initial centripetal growth
of the perimetrical epithelium; it formed a rim of translucent-pink
pearly colour which, during the following twelve days, characteri-
zed by the gradual reduction of the dosage of corticosteroids and
the suspension of the treatment with calcic heparin, was going pro-
gressively to cover the bloody area (Fig. 1D). Over twelve more
days, this was replaced by a delicate, serpiginous and discoloured
scar (Fig. 1E).
When the patient was discharged from hospital after 2
months, she was almost competely cured and she was advised to
follow a treatment programme under the supervision of her family
d o c t o r .
When she went for a follow-up examination after 1 year, the
scar had a firm appearance and there was no recurrence of PG or
clinical evidence of UC.
Discussion
PG is rarely encountered in clinical practice as an
isolated disease; in 75% of cases it is the cutaneous
manifestation of  an underlying systemic disease
(16,24); the latter in half of the cases is represented by a
c h ronic inflammatory bowel disease (2/3 by UC) (3,
43, 51, 59, 62, 70) and 1/3 by Crohn’s disease (22, 23,
51, 59, 62) and in the other half of cases by other disea-
ses such as arthritis (65), haematologic diseases (myelo-
proliferative disorders, Hodgkin’s disease, monoclonal
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gammopathy usually IgA, multiple myeloma, leukae-
mia) (27, 44, 50, 53, 58, 68) and some malignant neo-
plasms (of the breast, colon, prostate, bladder, carc i-
noid, lymphoma) (35, 36).
The PG incidence in chronic intestinal phlogosis
varies from 0.5 to 5% (3, 22, 43, 59) and is equivalent
on average to 1% in UC (2, 22, 23, 30, 51, 59).
PG is easily linked to serious, evo l u t i ve forms of
UC with total invo l vement of the large bowel, but it
has also been described in a small number of subjects
with light-to-moderate segmental disease (5 ,62, 70).
The case we have described, with phlogosis of medium
seriousness limited to the sigmoid-rectum area, is
included into this category; this demonstrates that
t h e re is not always a close correlation between the
seriousness and the extension of UC and the develop-
ment of cutaneous complications.
In more than half of the cases, PG continues in its
clinical course on an evident parallelism with the evo-
l u t i ve pro g ress of the intestinal disease: it arises and
worsens according to florid stages (initial or relapsing)
of UC, at the same time or after the beginning of colo-
nic symptoms (30); the clearing up of PG is linked to
the remission of the intestinal illness; it responds to
medical treatment of the underlying disorder and it is
susceptible to re g ression after total colectomy and in
only 10% of cases after proctocolectomy ( 2 0 ) .
On the contrary, in 20% of cases, the cutaneous
lesion continues in its clinical course which is indepen-
dent from the activity of the primary illness (70): it can
arise also some years before the UC and appears and
persists during the period of quiescence of the latter
(30); it responds badly, requiring additional therapy, to
direct treatment of the UC, bowel resection included;
and it can continue for a long time or develop ye a r s
after the operation of total colectomy or pro c t o c o l e c-
tomy (25, 41, 67).
The PG we have described, which appeared in the
acute phase of an underlying UC, represents its initial
manifestation and is the reason why the patient reque-
sted hospitalization; the recognition of PG allowed us,
after the suitable investigations of gastroenterology, to
reach the diagnosis of colonic inflammation in a sub-
clinical phase, since the latter had not been noticed
before.
The fact that PG can anticipate the beginning of
UC is clear proof of the theory that considers the two
manifestations, colonic and extracolonic, to be diffe-
rent clinical expressions of a single systemic disease, the
pathogenic cause of which acts independently both on
the large intestine, the main organ that is targeted, and
on other and tissues; the absence of a correlation between
the seriousness and the extension of UC and the cuta-
neous complication testifies the same hypothesis. On
the other hand, to give support to the theory that the
skin disorder is secondary to the bowel disease, we can
refer to the clinical data which marks its regression on
the occasion of the improvement of the underlying
pathology  and the beneficial effect that total colec-
tomy and proctocolectomy have on it. There f o re, the
relationship between UC and associated PG is still
u n k n own, as the exact etiological and pathogenetic
mechanism of the latter has not been demonstrated
and remains an enigma.
Although the term “p yo d e r m a” implies a bacterial
infection, this is not the cause of the lesion, which is
primarily sterile, and the possible discove ry of micro-
bial colonization does not have any etiological va l u e
since it is usually a case of suprainfection.
PG, on the contrary, can be attributed to a bad
regulation of the immunity of the organism with phe-
nomena on multiple areas of dangerous responsiveness
and of autoimmunity and to a bad functioning of poly-
morphonuclear leucocytes with defects in phagocytosis
and chemiotaxis (21, 45, 61).
Pa rticular attention must be paid to the pro b a b l e
role of mast cells activated and of the release of power-
ful inflammatory molecules contained in them and to
the suggestive but not well-defined role of the large
amounts of immunocomplexes circulating which
deposit themselves in the walls of the skin ve s s e l s ,
favouring the onset of vasculitis (9, 10, 41, 45, 52).
A common mediator invo l ves immunopathologic
c a u s a t i ve phenomena of PG and UC; this is re p re-
sented by a colonic antigen, if it is autologous, or by
an alimentary, bacterial, chemical kind of antigen, if
it is heterologous, because of an alterated state of per-
meability of the bowel wall by primary phlogosis (31,
42, 66).
The onset of PG on the site of an previous cuta-
neous trauma in 10-27% of cases (15, 38, 55), eve n
that small of endovenous injection, puts it into a cate-
gory of aspecific cutaneous hyperergia.
The single case of PG that we examined does not
allow us to enter in depth into the merits of the discus-
sion re l a t i ve to the etiology and pathogenesis of the
disease; we have limited ourselves to referring to the
hypotheses which emerged from the literature and we
have avoided expressing the conclusions that we oursel-
ves came to during the examination, since we could not
back them up by adequate experience.
The extracolonic complication of UC can be seen
especially in young, female patients (3), like the one
we observed, and can afflict any area of the skin,
though lesions of the lower limbs pre vail (57), espe-
cially in the pretibial region (54); lesions are rare l y
found on the head an neck (63), the penile and scro-
tal skin (60), the peristomal area (8, 47, 49) and the
a rea around laparotomies (17, 34). As far as we know,
t h e re are no other cases in the literature of PG situa-
ted in the space between the breasts, as in the case we
h a ve described.
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The diagnosis of PG is based, as in our case, prin-
cipally on the morphological peculiar characteri-
st ics , in a masterly fashion set  out in 1930 by
Brunsting (7).
The initial cutaneous lesion is re p resented by an
dermic erythematous nodule; it is hard, elastic, pain-
ful (papula) and, gradually, increases in size and in the
central part tends tow a rds colliquative necrosis with
the formation of a collection of non-septic puru l o i d
material, containing few polymorphonuclear cells and
no bacteria and cove red by a thin bluish epidermic
membrane (pustule). In a few days the collected mate-
rial may drain away of its own accord and in this way
an ulceration develops; with the pro g ression of necro-
tic phenomena and with almost inevitable secondary
bacterial colonization, it spreads in depth in the sub-
cutis and in a centrifugal sense tow a rds the surro u n-
ding areas at the speed of 1-2 cm/24 hours, leaving the
skin at first detached from the deep levels but then
that too is invo l ved in the necrosis. The sluggish, tere-
brant ulceration appears as an irre g u l a r, jagged form; it
is up to 30 cm in size and is quite painful; it has under-
mining, cribrate edges with several openings which
drain material that is puruloid or frankly purulent; the
edges violescent for the passive hyperaemia give rise,
a round the ulceration, 5-8 mm in width, to a blue,
shining halo and overlap a reddish base, sometimes
c ove red with necrotic, whitish tissue; a area of ery t h e-
ma spreads like an areola over the surrounding normal
s k i n .
In the case we have described, we did not encounter
t ox i c i t y, septicaemia with high fever or cutaneous
lesions associated with diverse typologies (nodose
e rythema, vesiculo-pustular lesions), which are often
seen in PG.
There are no pathognomonic laboratory data of the
cutaneous manifestation of UC which we have already
mentioned and the only positive results concern the
haematochemical ratios of the underlying disease,
including those immunopathological ones of dubious
interpretation.
The histopathological picture of PG is not specific
(66) and is only useful in order to exclude other possi-
ble pathologies. It is marked by a massive dermal
inflammatory infiltration, especially perivascular, com-
posed of polimorphonuclear leucocytes, histiocytes
and, at a later stage, lymphocytes; a vasculitis process is
present.
The histological investigation of the edges of the
u l c e r a t i ve cutaneous lesion we have illustrated show s
up a substantial presence of acidocytes, rather than the
ordinary detection of neutrophiles in the dermal infil-
tration of PG, included among neutrofile dermatosis
for this reason (4, 28). Howe ve r, this histological fin-
ding of ours is part of the various aspects seen in this
disease.
A differential diagnosis must consider the cuta-
neous ulcerations in the course of pathomimesis, those
of necrotizing vasculitis from hypersensibility (37) and
those that are bacterial, mycotic, mycobacterial, viral
and parasitic; venous and arterial ulcers situated in the
lower limbs must not be neglected.
The spontaneous healing of PG, a rare event, or its
healing following treatment takes place ve ry slow l y
with the cessation of the inflammatory process, the
beginning of reepithelization from the edges to the
c e n t re and the resulting in a serpiginous scar with
atrophic, iper-or ipo-pigmented skin (43, 57).
In 1/3 of cases, the cutaneous lesion recurs in the
same place or in another place (5, 43) and the smallest
trauma may be responsible for the relapse.
The treatment of PG is empiric and not codified.
Pharmacological treatment is aimed at contro l l i n g
the underlying UC and its remission which, in most
cases, is responsible for the improvement or the hea-
ling of the cutaneous ulcer (45, 70), although we can-
not exclude some favourable effect of treatment dire c-
tly on the skin disorder; howe ve r, we cannot quantify
this with accuracy. The treatment uses salazo p y r i n e
(43) or mesalazine and/or cort i c o s t e roids (pre d n i s o n e ,
p rednisolone, methylprednisolone) (6, 18), all on full
d o s a g e .
In PG that is resistant to the common treatment of
underlying UC and also in order to speed up the hea-
ling, topical treatment is worth trying.
Intralesional injections (in the edges of the ulcer) of
c o rt i c o s t e roids and likewise packs of water solution
with 2% disodium cromoglycate (11, 39) seem  to pro-
duce good results, but not always (19, 29); the thera-
peutic action of this substance is based on the inhibi-
tion of the liberation of chemical mediators by the
mast cells and the rise of the limit of reactivity.
As a support to specific treatment, systemic antibio-
tics doubtlessly are important in the definitive re m i s-
sion of the cutaneous lesion (minocycline; rifampicin
(13, 68) and topical (hyd rogen peroxide, benzoy l
p e roxide (48), with their contrasting action on its
secondary infection; also of relevance are all the other
local medical means concerning the wound bed prepa-
ration which, by keeping the necrosis away from the
ulceration with an action of debridement and stimula-
ting its granulation and reepithelization, actually
favour the regeneration and tissue repair and therefore
create the best healing conditions.
Good results have been noted with the use of
hyperbaric oxygen (69).
In the case of resistance of PG to the conventional
treatment of UC, we must not forget the use of immu-
nosuppressive (azathioprine, 6-mercaptopurine, meto-
t rexate, cyclophosphamide, chlorambucil, cyc l o s p o r i-
ne A ) (6, 9, 14, 40, 46) and anti-leprosy drugs, despite
the fact that we are uncertain about their modality of
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action on the skin disorder and the fact that they are
not always efficacious (clofazimine, dapsone ) (32, 33,
48, 64).
If non-invasive treatment of UC does not work on
the evolution of PG or if it persists or it becomes worse
it recurs, the efficacy of total colectomy has been poin-
ted out since it improves or totally clears up the cuta-
neous  lesion; this was also the experience of Goligher
(20) who, howe ve r, as we have already mentioned, in
10% of cases, saw the persistence of PG as long as the
rectal stump was left in place; howe ve r, after it was
taken away, PG suddenly disappeared. The surgical
e xcision of the intestine would offer, there f o re, the
excellent but drastic prospect of dominating the cuta-
neous disorder (30).
In the case of PG we studied, which proved to be
resistant to the usual medical treatment of the und-
erlying UC, we wanted to avoid the use of immuno-
suppressive drugs with their serious complications and
especially the highly debilitating total colectomy or the
p ro c t o c o l e c t o m y, considering also the endoscopic
i m p rovement of the intestinal situation. Th e re f o re ,
instead of these and alongside conventional treatment,
we decided to use infiltrations on the “active” edges of
the lesion of small doses of calcic heparin (5000 UI of
calcic heparin we re diluted in 10 cc of physiological
solution with which about 10 perilesional injections
were carried out on alternate days); this was done in an
e f f o rt to control, by exploiting the antithro m b o t i c
effect of the drug, those phenomena of vasculitis histo-
logically discovered on the edges of the skin disorder, in
the onset of which they have certainly physiopatholo-
gical importance.
The fact that topical antithrombotic tre a t m e n t
was successful in the single case of PG associated with
UC that we treated does not allow us to draw any
definite conclusions about its effectiveness in the hea-
ling of an ulcerative cutaneous lesion. We feel that,
up to now, it can and must re p resent only an additio-
nal medical therapy to be used side by side with cur-
rent treatment of PG; howe ve r, it must be given due
consideration in all cases in which PG is resistant to
the usual medical treatment of UC, since although
the skin disease, even if may predominate in the gene-
ral clinical situation because of its destru c t i ve quali-
ties, it cannot constitute an autonomous indication
for immunosuppre s s i ve drugs or for pro c t o c o l e c t o m y,
which should be re s o rted to only if the conditions of
the colon, after careful examination, impose it, since
the aforesaid treatments do not lead to an unequivo-
cal, definitive cure because their effect cannot be pre-
dicted with precision (25, 41, 67).
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